Biocon Launches Yesafili™ in U.S., Marking Milestone for Biosimilar Aflibercept
Biocon Ltd has announced the commercial launch of Yesafili™, a biosimilar aflibercept, in the United States. This launch establishes Yesafili™ as an FDA-approved interchangeable biosimilar to EYLEA® (aflibercept) 2 mg and is set to serve the ophthalmology market.Yesafili™, which is a vascular endothelial growth factor (VEGF) inhibitor, is intended for treating various serious eye conditions, including Neovascular (Wet) Age-Related Macular Degeneration (AMD), Diabetic Retinopathy (DR), and Macular Edema Following Retinal Vein Occlusion (RVO) or Diabetic Macular Edema (DME).
The launch comes as a significant development in addressing the growing need for effective treatment options. An estimated 19.8 million Americans are living with age-related macular degeneration (AMD). In 2023, U.S. sales of aflibercept reached approximately $5.89 billion, highlighting the substantial market opportunity for biosimilar alternatives like Yesafili™.
Shreehas Tambe, CEO and Managing Director at Biocon Ltd., stated that the introduction of Yesafili™ in the U.S. marks an important step in expanding the global availability of biosimilar Aflibercept 2 mg for patients with eye conditions. He added that this milestone reinforces Biocon’s presence in ophthalmology, building on its status as one of the first interchangeable biosimilars to Eylea® 2 mg and advancing access to life-changing medicines.
The approval and commercial launch of YESAFILI (aflibercept-jbvf) were supported by comprehensive analytical, nonclinical, and clinical data, which confirmed that Yesafili is highly similar to Eylea® 2 mg. A Phase 3 INSIGHT Study compared YESAFILI with Eylea® 2 mg in patients with Diabetic Macular Edema, demonstrating no clinically meaningful differences between the two products regarding pharmacokinetics, safety, efficacy, and immunogenicity.
The product holds an interchangeable designation granted by the U.S. Food and Drug Administration (FDA) as of May 2024, allowing for substitution at the pharmacy level in accordance with state laws.
Key details regarding the product launch and market presence are provided below:
| Particulars | Details |
|---|---|
| Product Name | Yesafili™ (aflibercept) |
| Date of Launch | August 03, 2026 |
| Category | Biosimilar |
| Market Focus | International market, specifically the United States |
| Target Conditions | AMD, Macular Edema Following RVO, Diabetic Retinopathy (DR), and DME |
| Status | FDA-approved interchangeable biosimilar to EYLEA 2 mg |
Biocon Ltd., a global biopharmaceutical company, operates across more than 120 countries, focusing on chronic and non-communicable diseases through its diversified portfolio of biosimilars and generics.
BIOCON Stock Price Movement
On Friday, Biocon Limited shares edged higher by 0.15% to close at ₹426.00, rising on a gain of ₹0.65 per share. The stock saw robust trading activity, with 2.3 million shares exchanging hands during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.